Recent network meta-analyses have raised concerns about the safety of biodegradable polymer drug-eluting stents (BP-DES) compared with durable polymer everolimus-eluting stents (DP-EES). [1]2][3] The NOBORI Biolimus-Eluting vs XIENCE/ PROMUS Everolimus-Eluting Stent Trial (NEXT) is a 98-center, randomized, open-label, noninferiority trial evaluating the efficacy and safety of biodegradable polymer biolimus-eluting stents (BP-BES) vs DP-EES. 4 The primary efficacy outcome of target-lesion revascularization (TLR) at 1 year demonstrated noninferiority of BP-BES compared with DP-EES. 4 The primary safety outcome, a composite of death and myocardial infarction (MI), will be reported at 3 years.However, because the advantages of BP-BES could emerge beyond 1 year when polymer has fully degraded, we report the interim 2-year results.
No takes yet. Share an insight, caveat, or question.
Natsuaki et al. (2014) studied this question.